Oral platelet glycoprotein IIb/IIIa receptor inhibitors-part I
نویسندگان
چکیده
منابع مشابه
Platelet Glycoprotein IIb/IIIa Inhibitors
Glycoprotein IIb/IIIa (GPIIb-IIIa) complexes (integrin aIIbb3) mediate platelet aggregation by binding fibrinogen or von Willebrand factor (vWF), protein cofactors that form bridges between adjacent platelets. The cross-linked adhesive proteins assemble platelets into the aggregate. Agents that block the function of the GPIIb-IIIa complex of platelets constitute a powerful new generation of ant...
متن کاملPlatelet glycoprotein IIb/IIIa inhibitors.
To the Editor: Platelet glycoprotein (GP) IIb/IIIa antagonists only prompt an overall 8.5% relative reduction in 30-day deaths or myocardial infarction in acute coronary syndromes (ACS),1 and Quinn et al1 suggested that this limited benefit may be due to factors such as antagonist-induced platelet activation. I suggest that limited benefits of GP IIb/IIIa inhibition are due basically to limited...
متن کاملMedical decision making with incomplete evidence--choosing a platelet glycoprotein IIbIIIa receptor inhibitor for percutaneous coronary interventions.
BACKGROUND Medical decision making must often be performed despite incomplete evidence. An example is the choice of a glycoprotein IIb/IIIa (GP2b3a) inhibitor, a class of potent antiplatelet medications, as adjunctive therapy during percutaneous coronary interventions (PCIs). GP2b3a inhibitor efficacy in reducing adverse outcomes has been well documented with multiple placebo-controlled randomi...
متن کاملDrug-eluting stents and glycoprotein IIbIIIa inhibitors in the pharmacoinvasive management of ST elevation MI
Evaluation of: Sanchez, P, Gimeno F, Ancillo P et al.: Role of the paclitaxel-eluting stent and tirofiban in patients with ST elevation myocardial infarction undergoing postfibrinolysis angioplasty (GRACIA 3 Trial). Circ. Cardiovasc. Interv. 3, 297–307 (2010). In ST elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention (PCI)-capable hospitals, a pharmacoin...
متن کاملAcquired thrombasthenia due to inhibitory effect of glycoprotein IIbIIIa autoantibodies.
BACKGROUND A 75 year old patient presenting with mucocutaneous bleeding was diagnosed with acquired thrombasthenia. The diagnosis was based on lack of platelet aggregation with adenosine diphosphate (ADP), arachidonic acid and collagen, and normal aggregation induced by ristocetin. OBJECTIVE To study the mechanism of platelet function inhibition in a patient with acquired thrombasthenia. ME...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cardiology
سال: 2003
ISSN: 0160-9289,1932-8737
DOI: 10.1002/clc.4950260803